KR20210122163A - Plk1의 선택적 분해를 유도하는 피라졸로퀴나졸린 유도체 화합물 - Google Patents

Plk1의 선택적 분해를 유도하는 피라졸로퀴나졸린 유도체 화합물 Download PDF

Info

Publication number
KR20210122163A
KR20210122163A KR1020210040036D KR20210040036D KR20210122163A KR 20210122163 A KR20210122163 A KR 20210122163A KR 1020210040036 D KR1020210040036 D KR 1020210040036D KR 20210040036 D KR20210040036 D KR 20210040036D KR 20210122163 A KR20210122163 A KR 20210122163A
Authority
KR
South Korea
Prior art keywords
formula
plk1
compound
mmol
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
KR1020210040036D
Other languages
English (en)
Korean (ko)
Inventor
최시우
류수희
류지훈
손산하
이화진
김성훈
남보아스
민임숙
류혜국
강금영
Original Assignee
(주) 업테라
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by (주) 업테라 filed Critical (주) 업테라
Publication of KR20210122163A publication Critical patent/KR20210122163A/ko
Granted legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
KR1020210040036D 2020-03-27 2021-03-27 Plk1의 선택적 분해를 유도하는 피라졸로퀴나졸린 유도체 화합물 Granted KR20210122163A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20200037875 2020-03-27
KR1020200037875 2020-03-27

Publications (1)

Publication Number Publication Date
KR20210122163A true KR20210122163A (ko) 2021-10-08

Family

ID=77892014

Family Applications (8)

Application Number Title Priority Date Filing Date
KR1020210040036D Granted KR20210122163A (ko) 2020-03-27 2021-03-27 Plk1의 선택적 분해를 유도하는 피라졸로퀴나졸린 유도체 화합물
KR1020210040038D Granted KR20210122165A (ko) 2020-03-27 2021-03-27 Plk1의 선택적 분해를 유도하는 바닐린 유도체 화합물
KR1020210040036A Active KR102313752B1 (ko) 2020-03-27 2021-03-27 Plk1의 선택적 분해를 유도하는 피라졸로퀴나졸린 유도체 화합물
KR1020210040037D Granted KR20210122164A (ko) 2020-03-27 2021-03-27 Plk1의 선택적 분해를 유도하는 벤즈이미다졸 티오펜 유도체 화합물
KR1020210040035A Active KR102337029B1 (ko) 2020-03-27 2021-03-27 Plk1 선택적 분해 유도 화합물
KR1020210040038A Active KR102313753B1 (ko) 2020-03-27 2021-03-27 Plk1의 선택적 분해를 유도하는 바닐린 유도체 화합물
KR1020210040037A Active KR102319264B1 (ko) 2020-03-27 2021-03-27 Plk1의 선택적 분해를 유도하는 벤즈이미다졸 티오펜 유도체 화합물
KR1020210171223A Active KR102529222B1 (ko) 2020-03-27 2021-12-02 Plk1 선택적 분해 유도 화합물

Family Applications After (7)

Application Number Title Priority Date Filing Date
KR1020210040038D Granted KR20210122165A (ko) 2020-03-27 2021-03-27 Plk1의 선택적 분해를 유도하는 바닐린 유도체 화합물
KR1020210040036A Active KR102313752B1 (ko) 2020-03-27 2021-03-27 Plk1의 선택적 분해를 유도하는 피라졸로퀴나졸린 유도체 화합물
KR1020210040037D Granted KR20210122164A (ko) 2020-03-27 2021-03-27 Plk1의 선택적 분해를 유도하는 벤즈이미다졸 티오펜 유도체 화합물
KR1020210040035A Active KR102337029B1 (ko) 2020-03-27 2021-03-27 Plk1 선택적 분해 유도 화합물
KR1020210040038A Active KR102313753B1 (ko) 2020-03-27 2021-03-27 Plk1의 선택적 분해를 유도하는 바닐린 유도체 화합물
KR1020210040037A Active KR102319264B1 (ko) 2020-03-27 2021-03-27 Plk1의 선택적 분해를 유도하는 벤즈이미다졸 티오펜 유도체 화합물
KR1020210171223A Active KR102529222B1 (ko) 2020-03-27 2021-12-02 Plk1 선택적 분해 유도 화합물

Country Status (6)

Country Link
US (5) US12403198B2 (https=)
EP (1) EP3911654A4 (https=)
JP (2) JP7440940B2 (https=)
KR (8) KR20210122163A (https=)
CN (1) CN113784969A (https=)
WO (4) WO2021194321A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12551563B2 (en) 2019-09-27 2026-02-17 Dana-Farber Cancer Institute, Inc. ERK5 degraders as therapeutics in cancer and inflammatory diseases
KR20210122163A (ko) * 2020-03-27 2021-10-08 (주) 업테라 Plk1의 선택적 분해를 유도하는 피라졸로퀴나졸린 유도체 화합물
CA3226162A1 (en) 2021-07-09 2023-01-12 Plexium, Inc. Aryl compounds and pharmaceutical compositions that modulate ikzf2
PE20240894A1 (es) * 2021-08-10 2024-04-24 Uppthera Inc Compuesto inductor de la degradacion de plk1 novedoso
TW202321219A (zh) 2021-08-11 2023-06-01 大陸商四川海思科製藥有限公司 雜環衍生物及其組合物和藥學上的應用
CN114380682A (zh) * 2021-10-27 2022-04-22 上海毕得医药科技股份有限公司 一种2,3-二氟-4-甲氧基苯乙酸合成方法
WO2023104195A1 (zh) * 2021-12-10 2023-06-15 正大天晴药业集团股份有限公司 一种异噻唑并[5,4-d]嘧啶类IRAK4抑制剂的制备方法
CN118382626A (zh) * 2021-12-10 2024-07-23 山东绿叶制药有限公司 蛋白激酶抑制剂及其制备方法和应用
CN116924929A (zh) * 2022-07-08 2023-10-24 重庆圣华曦药业股份有限公司 一种碘比醇异构体的合成方法
CN115490675B (zh) * 2022-09-19 2024-11-12 安阳师范学院 季酮酸衍生物及其制备方法与应用
EP4626889A4 (en) * 2022-11-29 2026-03-18 Uppthera Inc COMPOUNDS INDUCING THE DEGRADATION OF PLK1 WITH INCREASED STIFFNESS
EP4653443A1 (en) * 2023-01-17 2025-11-26 Phil Rivers Technology Co., Ltd Stereoisomer and deuterated derivative of pyrazoloquinazoline compound and use
CN119790057A (zh) * 2023-02-02 2025-04-08 厄普特拉株式会社 新型plk1降解诱导化合物
CN116554044A (zh) * 2023-05-16 2023-08-08 上海师范大学 一种无氨基保护的2,6-二异丙基-4-羧基苯胺及其合成方法
KR20250058831A (ko) 2023-10-23 2025-05-02 주식회사 펩토이드 Ｐｌｋ－１의 폴로박스 도메인에 결합하는 저분자 화합물을 함유하는 항암제
WO2025239662A1 (ko) * 2024-05-13 2025-11-20 (주) 업테라 분해 약물-항체 접합체용 plk1 분해 유도 화합물
CN119707950A (zh) * 2024-12-24 2025-03-28 无锡市南京大学锡山应用生物技术研究所 一种用于免疫蛋白靶向降解的嵌合体及其制备方法和应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA014111B1 (ru) 2005-09-06 2010-10-29 Смитклайн Бичем Корпорейшн Бензимидазолтиофеновые соединения в качестве ингибиторов polo-подобных киназ (plk)
MX2009006613A (es) * 2006-12-21 2009-07-02 Nerviano Medical Sciences Srl Derivados de pirazolo-quinazolina sustituidos, proceso para su preparacion y su uso como inhibidores de cinasa.
AU2008228303B2 (en) * 2007-03-22 2012-04-19 Takeda Pharmaceutical Company Limited Substituted pyrimidodiazepines useful as PLK1 inhibitors
EP2205241B1 (en) * 2007-09-25 2014-05-21 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
EP2303889A1 (en) 2008-06-18 2011-04-06 F. Hoffmann-La Roche AG Halo-substituted pyrimidodiazepines as plkl inhibitors
AR076784A1 (es) 2009-05-26 2011-07-06 Nerviano Medical Sciences Srl Combinacion terapeutica que comprende un inhibidor de plk1 y un agente antineoplasico
KR102668696B1 (ko) * 2012-01-12 2024-05-29 예일 유니버시티 E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
RU2738833C9 (ru) 2014-04-14 2022-02-28 Арвинас, Оперэйшнз, Инк. Имидные модуляторы протеолиза и способы их применения
EP3270917A4 (en) 2015-03-18 2018-08-08 Arvinas, Inc. Compounds and methods for the enhanced degradation of targeted proteins
WO2016197114A1 (en) * 2015-06-05 2016-12-08 Arvinas, Inc. Tank-binding kinase-1 protacs and associated methods of use
BR112018008918A8 (pt) 2015-11-02 2019-02-26 Univ Yale compostos de quimera proteólise dirigida e métodos para preparação e uso dos mesmos
US20170281784A1 (en) 2016-04-05 2017-10-05 Arvinas, Inc. Protein-protein interaction inducing technology
CN106543185B (zh) 2016-11-10 2017-12-15 吉林大学 一种靶向泛素化降解plk1和brd4蛋白的化合物及其应用
IL312367A (en) * 2017-01-31 2024-06-01 Arvinas Operations Inc Cereblon ligands and bifunctional compounds comprising the same
CN106977584B (zh) * 2017-04-19 2019-12-06 吉林大学 靶向泛素化降解plk1和brd4蛋白的化合物及其应用
CA3085645C (en) 2017-12-13 2024-01-16 Shanghaitech University Alk protein degraders and their use in cancer therapy
KR102127289B1 (ko) * 2018-09-18 2020-06-26 고려대학교 산학협력단 암 세포를 표적화하기 위한 plk 선택적 형광 프로브 화합물 및 이를 포함하는 plk 검출용 형광 센서
CN111018857B (zh) * 2018-10-09 2023-06-02 嘉兴优博生物技术有限公司 靶向蛋白酶降解平台(ted)
CN109879877B (zh) 2019-03-04 2021-08-10 吉林大学 一种可降解plk1和brd4蛋白的化合物及其应用
KR20210122163A (ko) * 2020-03-27 2021-10-08 (주) 업테라 Plk1의 선택적 분해를 유도하는 피라졸로퀴나졸린 유도체 화합물
PE20240894A1 (es) * 2021-08-10 2024-04-24 Uppthera Inc Compuesto inductor de la degradacion de plk1 novedoso

Also Published As

Publication number Publication date
WO2021194321A1 (en) 2021-09-30
KR20210122165A (ko) 2021-10-08
US20230203006A1 (en) 2023-06-29
US12403198B2 (en) 2025-09-02
JP7440940B2 (ja) 2024-02-29
EP3911654A1 (en) 2021-11-24
WO2021194319A1 (en) 2021-09-30
CN113784969A (zh) 2021-12-10
KR102319264B1 (ko) 2021-11-01
WO2021194320A1 (en) 2021-09-30
US20230372498A1 (en) 2023-11-23
KR102313753B1 (ko) 2021-10-19
US11833208B2 (en) 2023-12-05
JP2023171659A (ja) 2023-12-01
EP3911654A4 (en) 2022-05-11
KR102529222B1 (ko) 2023-05-08
KR20210150341A (ko) 2021-12-10
US20230104076A1 (en) 2023-04-06
KR102313752B1 (ko) 2021-10-19
US20230159515A1 (en) 2023-05-25
US20230158158A1 (en) 2023-05-25
WO2021194318A1 (en) 2021-09-30
JP2022539579A (ja) 2022-09-12
KR20210122164A (ko) 2021-10-08
KR20210122162A (ko) 2021-10-08
KR102337029B1 (ko) 2021-12-09

Similar Documents

Publication Publication Date Title
KR102313752B1 (ko) Plk1의 선택적 분해를 유도하는 피라졸로퀴나졸린 유도체 화합물
CN116113632B (zh) 杂环类衍生物、其制备方法及其医药上的用途
AU752186B2 (en) Thrombin inhibitors
CN116514846A (zh) 杂环类衍生物、其制备方法及其医药上的用途
CN116162099A (zh) 杂环类衍生物及其制备方法和用途
KR20150129010A (ko) Ido 억제제
JP7398135B2 (ja) ユビキチン特異的プロテアーゼ阻害剤及びその製造方法と応用
EP2938610A2 (en) Inhibitors of the usp1/uaf1 deubiquitinase complex and uses thereof
JP2022188014A (ja) バニン阻害剤としてのヘテロ芳香族化合物
US20240317711A1 (en) Aurka selective degradation inducing compound
KR20220044753A (ko) 아세틸 조효소 a 신테타제 단쇄 2(acss2)의 소분자 억제제
EP4602043A1 (en) 4h-pyrido[1,2-a]pyrimidin-4-one derivatives for treating cancer
KR20210103973A (ko) 단백질 키나아제 분해 유도 화합물 및 이의 용도
WO2014074665A1 (en) Macrocyclic compounds for inhibition of inhibitors of apoptosis
CN112538084A (zh) 新颖的kras g12c蛋白抑制剂及其制备方法和用途
KR102574152B1 (ko) Plk1의 선택적 분해를 유도하는 벤즈이미다졸 티오펜 유도체 화합물
KR20260035802A (ko) 새로운 mettl3 억제제 및 치료에서의 이의 용도
KR102539761B1 (ko) 2-티옥소티아졸리딘-4-온 유도체 화합물 및 이의 용도
AU2021436754B2 (en) Bicyclic heterocyclic fgfr4 inhibitor, pharmaceutical composition and preparation comprising same, and application thereof
KR20230070166A (ko) Gpx4 단백질 분해 유도 화합물
CN119462554A (zh) 一种hdac抑制剂及其制备、用途
CN119100980A (zh) 一类含芳环并吡啶酮酰胺的化合物
Zhou et al. Discovery of the First Potent Ror1 Degrader for the Treatment of Non-Small Cell Lung Cancer

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R17-X000 Change to representative recorded

St.27 status event code: A-5-5-R10-R17-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000